(Press-News.org) Vienna, Austria: Instead of stabbing yourself, or someone else, in the thigh with a needle to deliver a dose of adrenaline to counter anaphylactic shock, would it not be easier to use a nasal spray instead?
A study presented at the European Emergency Medicine Congress today (Tuesday) shows that liquid or powder nasal sprays are as effective and sometimes even better than injection devices such as EpiPens® for delivering adrenaline [1].
Anaphylaxis is an acute allergic reaction to substances, such as nuts or insect bites or stings, and is a life-threatening emergency. A patient who goes into anaphylactic shock will often develop some or all of the following symptoms: itchy skin or a red rash, swollen eyes, hands, feet, mouth, tongue and throat, difficulty breathing, wheeze, abdominal pain, nausea and vomiting. They can collapse and become unconscious very quickly. It needs to be treated urgently with adrenaline (also known as epinephrine), usually via an injection or a drip in the patient’s vein.
Dr Danielle Furness carried out a systematic review of five, international studies comparing intramuscular-injected adrenaline devices, such as EpiPens®, with nasal sprays while she was finishing her medical degree at the University of Buckingham, UK. The studies took place in Israel, Canada, Thailand, the USA and Japan [2].
She told the Congress: “My review found that intranasal adrenaline, a needle-free alternative delivered as a liquid or dry powder spray, can be as effective as the EpiPen, with some forms reaching the bloodstream even faster.”
Dr Furness, who is now a Foundation Year 1 doctor at the Royal Derby Hospital, UK, chose to compare emerging options for anaphylaxis, such as nasal sprays, with current guidelines and the gold standard recommendations while she was studying acute care for her degree. She focused on needle-free alternatives for patients with needle phobia or other barriers to using EpiPens®.
She evaluated the safety and efficacy of the different adrenaline delivery systems, and also the pharmacokinetics – the process of how the drug moves into, through and out of the body, focusing on absorption, distribution and metabolism.
She found that absorption of the nasal sprays was comparable or even faster than injections, taking a maximum of 2.5 to 20 minutes, compared to 9 to 45 minutes for the injected adrenaline. Similar or higher levels of adrenaline were seen in blood plasma for the nasal sprays, while heart rate and blood pressure were similar between patients who received adrenaline via a nasal spray or an injection. Side effects of the nasal spray were mild and passed quickly.
Importantly, nasal sprays last longer and are more portable than injection devices. The shelf life of nasal sprays is two years, while injection devices have to be replaced every 12-18 months. The nasal sprays tend to be smaller and more portable than injection devices, such as the EpiPen®. The neffy® nasal spray is just over six centimetres long, while an EpiPen® is just over 15 cm long.
Dr Furness said: “If approved for use, nasal sprays could become a suitable and equally effective needle-free alternative to the EpiPen, which is the current treatment for anaphylaxis. Patients would still need clear instructions on how and when to use a nasal spray, but it could improve timely administration of adrenaline, especially for people who are afraid of needles, or in public, out-of-hospital settings, which could reduce the rates of hospitalisations. For doctors, it is another tool that could help prevent delays in treatment.
“I believe that once strong, real-world evidence supports the safety and effectiveness of nasal sprays, they could be incorporated into national anaphylaxis guidelines. An initial rollout should include close and strict monitoring, encouraging doctors to report any cases where it may not have worked as expected, to ensure patient safety and maintain confidence in the treatment.”
Neffy® is the first nasal spray to be approved and prescribed in the USA and Europe, including Norway and Iceland. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved it as the first needle-free emergency treatment for anaphylaxis. It is expected to become available in the UK towards the end of 2025. Licensing applications have been filed in China, Japan, and Australia, and it is under review in Canada.
Strengths of the review include that it looked at both liquid and dry powder based nasal spray, comparing them directly to the current gold standard of injected adrenaline; it investigated the effects of the different delivery systems on blood pressure and heart rate, and not just how quickly the drug entered the bloodstream; and the trials were carried out in several different countries.
Limitations include that all the studies were early, phase I trials, in which the different delivery systems are tested in healthy adults who were not experiencing anaphylaxis; some of the studies reviewed had small numbers of patients and there were differences in the doses and delivery devices tested; there are no long-term safety data yet; and it is uncertain how the nasal sprays will perform in everyday use outside of controlled trial conditions.
Dr Felix Lorang is a member of the EUSEM abstract selection committee. He is head of the emergency department at SRH Zentralklinikum Suhl, Thuringia, Germany, and was not involved with the research. He said: “Injection devices, such as EpiPens, have been in use for decades to deliver adrenaline to patients with anaphylaxis. However, some patients experience barriers to using them for reasons such as needle phobia, or how easy they are to carry around all the time. From my experience, many people also hesitate when using a needle on a relative or friend for fear of hurting or injuring the person. Nasal sprays appear to overcome these barriers and, if further studies confirm their safety and efficacy, they will be a useful alternative for patients as well as an extra tool for medical staff to use.”
(ends)
[1] Abstract no: OA063, “Intranasal adrenaline in comparison with intramuscular adrenaline for adults with anaphylaxis: a systematic review of pharmacokinetics, safety, and efficacy” Danielle Furness, Infectious diseases session, Tuesday 30 September, 14:45-16:15 hrs CEST, Schubert 4 room: https://eusem.floq.live/kiosk/eusem-2025/dailyprogramme?objectClass=timeslot&objectId=68871e9e626af251d24be3d3&type=detail
[2] The five studies were:
A trial of FMXIN002 – a dry powder nasal spray – in Israel and Canada
A study of the pharmacokinetics of a nasal spray in Thailand
A phase I trial of a nasal spray, called neffy® in the USA and Japan
A study of a nasal spray compared to injected adrenaline in the USA and Canada
An analysis of several trials looking at 13.2 mg nasal sprays in the USA. END
Could nasal sprays replace needles for delivering adrenaline to anaphylactic patients?
2025-09-29
ELSE PRESS RELEASES FROM THIS DATE:
Children lose 8.45 million days of healthy life due to second hand smoke
2025-09-29
Children lose 8.45 million days of healthy life each year globally due to second hand smoke, according to research presented at the European Respiratory Society Congress in Amsterdam, the Netherlands [1]. Children from low socio-economic regions face the biggest impact of breathing second hand smoke, also known as passive smoking.
The study was presented by Dr Siyu Dai, Assistant Professor in the School of Clinical Medicine at Hangzhou Normal University and an Honorary Research Associate in the Department of Paediatrics at The Chinese University of Hong Kong.
She told the Congress: “Second-hand smoke is a major contributor ...
Indoor wood burners linked to a decline in lung function
2025-09-29
Using a wood burning stove at home can lead to a decline in lung function, according to research presented at the European Respiratory Society Congress in Amsterdam, the Netherlands [1].
The study was presented by Dr Laura Horsfall, Principal Research Fellow from the Institute of Health Informatics, University College London, UK.
The use of solid fuel for domestic heating has increased in Europe due to the marketing of wood as renewable energy and high fossil fuel prices. In the UK, the proportion of harmful ...
Yale researchers develop novel test for leptospirosis
2025-09-29
New Haven, Conn. — In a new study, Yale School of Medicine (YSM) researchers unveiled a novel diagnostic method for detecting leptospiral virulence-modifying (VM) proteins in the blood and urine of hamsters, an advance that could pave the way for early diagnosis of the tropical disease leptospirosis in humans and improved treatment options. The findings were published in the journal Microbiology Spectrum.
Found around the world, leptospirosis affects approximately 1 million people annually, with nearly 60,000 fatalities. The disease is caused by the bacterium Leptospira and is spread ...
Medicaid unwinding associated with less medication treatment for opioid use disorder
2025-09-29
The end of pandemic-era enrollment enhancements for Medicaid was associated with a rise in the number of people ending medication treatment for opioid use disorder, as well as a decrease in the number of people beginning such treatment, according to a new RAND study.
While some people who disenrolled from Medicaid may have found other methods to pay for drug treatment, the overall number of those initiating and continuing medication treatment for opioid use disorder declined in the six months after Medicaid unwinding began. The changes were greatest in states that have had the largest disenrollments.
The study ...
Rapid flash Joule heating technique unlocks efficient rare‑earth element recovery from electronic waste
2025-09-29
A team of researchers including Rice University’s James Tour and Shichen Xu has developed an ultrafast, one-step method to recover rare earth elements (REEs) from discarded magnets using an innovative approach that offers significant environmental and economic benefits over traditional recycling methods. Their study was published in the Proceedings of the National Academy of Sciences Sept. 29, 2025.
Conventional rare earth recycling is energy-heavy and creates toxic waste. The research team’s method uses flash Joule heating (FJH), which rapidly raises material temperatures to thousands of degrees within milliseconds, and chlorine gas to extract REEs from ...
First randomized study comparing proton and photon radiation therapy for breast cancer finds both preserve quality of life
2025-09-29
SAN FRANCISCO, September 29, 2025 — The first randomized trial to compare photon- and proton-based radiation therapy for breast cancer finds that patients report equally strong health-related quality of life with either treatment. Patients who received proton therapy were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.
The phase III Radiotherapy Comparative Effectiveness (RadComp) trial enrolled more than 1,200 patients, making it also the largest head-to-head comparison of photon and proton therapy for any ...
Shorter radiation improves patient experience but not disease control for intermediate-risk prostate cancer
2025-09-29
SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to results of a large, randomized phase III trial. Patients treated with stereotactic body radiation therapy (SBRT) reported fewer declines in bowel, urinary and sexual functioning but were more likely to experience a rise in prostate-specific antigen (PSA). Initial results of the NRG Oncology GU005 ...
Scientists successfully recreate wildfire-induced thunderstorms in Earth system models for the first time
2025-09-29
On September 5, 2020, California’s Creek Fire grew so severe that it began producing it’s own weather system. The fire’s extreme heat produced an explosive thunderhead that spewed lightning strikes and further fanned the roaring flames, making containment elusive and endangering the lives of firefighters on the ground. These wildfire-born storms have become a growing part of fire seasons across the West, with lasting impacts on air quality, weather, and climate. Until now, scientists have struggled to replicate them in Earth system models, hindering our ability to predict their occurrence ...
AI tool may enable opportunistic assessment of body composition from routine imaging, identify patients at cardiovascular risk
2025-09-29
Embargoed for release until 5:00 p.m. ET on Monday 29 September 2025
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and Linkedin
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of ...
Too heavy for medical care: Over 40% of specialty clinics turn away patients weighing 465 pounds
2025-09-29
One in 270 Americans (nearly 1 million adults) has a BMI of 60 or greater
More than half of surveyed clinics lacked exam tables, chairs and/or gowns for patients weighing 450 pounds
Receptionists made stigmatizing comments: ‘We’ve reached our limit for bariatric patients’
Patients with obesity are less likely to get cancer screenings and preventive care
CHICAGO --- Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.
The scientists used a “secret-shopper” method to attempt to schedule an appointment ...